Review
Andrology
Hui-Yu Dong, Lei Ding, Tian-Ren Zhou, Tao Yan, Jie Li, Chao Liang
Summary: Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional network shifted. Forkhead box protein A1 (FOXA1) may play a key role in this process through multiple mechanisms. Future efforts need to focus on mechanisms underlying mutation of FOXA1 in advanced prostate cancer. We believe that FOXA1 would be a prognostic marker and therapeutic target in prostate cancer.
ASIAN JOURNAL OF ANDROLOGY
(2023)
Review
Medicine, Research & Experimental
Joanna Dulinska-Litewka, Dominik Felkle, Kacper Dykas, Zuzanna Handziuk, Marta Krzysztofik, Bartosz Gasiorkiewicz
Summary: The role of cyclins in hormone-dependent neoplasms, especially breast cancer, is crucial. However, cyclins in prostate cancer are less studied, particularly the role of other cyclins that requires further investigation. Recent studies have shown that cyclins not only regulate the cell cycle but also interact with other signaling pathways. The androgen signaling axis plays a significant role in prostate cancer progression and interferes with cyclin pathways.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Cell Biology
Marco Del Giudice, John G. Foster, Serena Peirone, Alberto Rissone, Livia Caizzi, Federica Gaudino, Caterina Parlato, Francesca Anselmi, Rebecca Arkell, Simonetta Guarrera, Salvatore Oliviero, Giuseppe Basso, Prabhakar Rajan, Matteo Cereda
Summary: FOXA1 plays a key role in dysregulation of alternative splicing in prostate cancer by controlling transcription factor expression and binding to splicing-related genes, leading to the production of dominant isoforms and influencing patient survival.
Article
Biochemistry & Molecular Biology
Laura Helminen, Jasmin Huttunen, Melina Tulonen, Niina Aaltonen, Einari A. Niskanen, Jorma J. Palvimo, Ville Paakinaho
Summary: Prostate cancer treatment relies on inhibiting androgen receptor (AR) signaling, but resistance to antiandrogen therapy is still not well understood. This study used genome-wide techniques to discover crucial features of glucocorticoid receptor (GR) action in prostate cancer cells, providing new insights into the mechanisms of antiandrogen resistance.
NUCLEIC ACIDS RESEARCH
(2023)
Article
Multidisciplinary Sciences
Su H. Park, Ka-wing Fong, Jung Kim, Fang Wang, Xiaodong Lu, Yongik Lee, Lourdes T. Brea, Kristine Wadosky, Chunming Guo, Sarki A. Abdulkadir, John D. Crispino, Deyu Fang, Panagiotis Ntziachristos, Xin Liu, Xue Li, Yong Wan, David W. Goodrich, Jonathan C. Zhao, Jindan Yu
Summary: This study reveals that FOXA1 is a nonhistone substrate of enhancer of zeste homolog 2 (EZH2) which methylates FOXA1 at lysine-295. The methylation is recognized by WD40 repeat protein BUB3 and recruited ubiquitin-specific protease 7 (USP7) to enhance FOXA1 protein stability. EZH2 inhibitors may be leveraged to enhance therapeutic targeting of FOXA1-driven PCa growth.
Review
Oncology
Zoran Culig
Summary: Prostate cancer is the most frequently diagnosed non-cutaneous tumor in men in the Western world. Anti-androgens like bicalutamide are commonly used in therapy for non-organ confined prostate cancer. Cytokines, especially interleukins, can affect tumor cells' response to anti-androgens and more clinical trials are needed to improve this interaction.
Article
Cell Biology
Marzia Di Donato, Pia Giovannelli, Maria Vittoria Barone, Ferdinando Auricchio, Gabriella Castoria, Antimo Migliaccio
Summary: This study demonstrates the association of androgen receptor with Filamin A in promoting migration and invasiveness of prostate cancer-derived cells, suggesting that targeting the AR/FlnA complex could improve the clinical management of invasive prostate cancer.
Review
Biochemistry & Molecular Biology
Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh
Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Review
Oncology
Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri
Summary: The review discusses the role of FOXA1 in regulating gene activity, cell biology, and the response of breast cancers to hormone therapies. It also highlights the potential for future studies to explore the roles of FOXA1 independent of its regulation of nuclear receptors.
Article
Oncology
Yingxue Gao, Yijun Liu, Youhong Liu, Yuchong Peng, Bowen Yuan, Yuxin Fu, Xuli Qi, Qianling Zhu, Tuoyu Cao, Songwei Zhang, Linglong Yin, Xiong Li
Summary: UHRF1 and CDC6, oncogenes that play critical roles in therapeutic resistance, are upregulated simultaneously in prostate cancer, where UHRF1 promotes CDC6 transcription controlled by AR through chromatin modification, contributing to anti-AR drug resistance and worse survival. Targeting both AR and UHRF1 simultaneously could be a novel and promising therapeutic approach for prostate cancer.
Article
Multidisciplinary Sciences
C. Kalogirou, J. Linxweiler, P. Schmucker, M. T. Snaebjornsson, W. Schmitz, S. Wach, M. Krebs, E. Hartmann, M. Puhr, A. Mueller, M. Spahn, A. K. Seitz, T. Frank, H. Marouf, G. Buechel, M. Eckstein, H. Kuebler, M. Eilers, M. Saar, K. Junker, F. Roehrig, B. Kneitz, M. T. Rosenfeldt, A. Schulze
Summary: The downregulation of miR-205 promotes cholesterol synthesis and androgen receptor signaling in aggressive prostate cancer by enhancing the expression of the rate-limiting enzyme squalene epoxidase. Overexpression of squalene epoxidase in advanced prostate cancer correlates with poor survival, indicating its potential as a therapeutic target. Inhibition of squalene epoxidase with terbinafine effectively blocked tumor growth in mice and reduced levels of prostate specific antigen in late-stage prostate cancer patients.
NATURE COMMUNICATIONS
(2021)
Article
Urology & Nephrology
Samuel Tremblay, Lily Summers-Trasiewicz, Frederic Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, Paul Toren
Summary: This study aimed to evaluate the relationship between testosterone levels and PSA levels during ADT and its impact on clinical outcomes. The results showed that testosterone levels had a smaller prognostic effect compared to PSA levels on outcomes. Specifically, there was no significant association between the cumulative testosterone exposure and outcomes.
JOURNAL OF UROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Haozhe Zhang, Yi Zhou, Zengzhen Xing, Rajiv Kumar Sah, Junqi Hu, Hailiang Hu
Summary: This review discusses the close relationship between the evolution of prostate cancer and androgen levels and the status of the androgen receptor. It also explores how alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Jasna Metovic, Fulvio Borella, Marta D'Alonzo, Nicoletta Biglia, Luca Mangherini, Cristian Tampieri, Luca Bertero, Paola Cassoni, Isabella Castellano
Summary: This review article summarizes the roles of the forkhead box A1 protein (FOXA1) in normal and neoplastic tissues, with a focus on its prognostic and predictive role in breast cancer. FOXA1, as a pioneer factor and interacting partner of estrogen and androgen receptors, plays a crucial role in breast cancer development and progression. Its expression has been found to have a significant impact on prognosis and treatment response in breast cancer, making it a potential prognostic and predictive marker. Immunohistochemistry can be used to detect FOXA1 expression and it could be considered for routine diagnostics in breast cancer.
Article
Biochemistry & Molecular Biology
Y. He, Y. Zhao, L. Wang, L. R. Bohrer, Y. Pan, H. Huang
Article
Multidisciplinary Sciences
Chunjie Sheng, Chen Yao, Ziyang Wang, Hongyuan Chen, Yu Zhao, Dazhi Xu, Haojie Huang, Wenlin Huang, Shuai Chen
NATURE COMMUNICATIONS
(2018)
Article
Biochemistry & Molecular Biology
Yu Zhao, Liya Ding, Dejie Wane, Zhenqing Ye, Yundong He, Linlin Ma, Runzhi Zhu, Yunqian Pan, Qiang Wu, Kun Pang, Xiaonan Hou, Saravut J. Weroha, Conghui Han, Roger Coleman, Ilsa Coleman, R. Jeffery Karnes, Jun Zhang, Peter S. Nelson, Liguo Wang, Haojie Huang
Article
Medicine, Research & Experimental
Yuqian Yan, Jian Ma, Dejie Wang, Dong Lin, Xiaodong Pang, Shangqian Wang, Yu Zhao, Lei Shi, Hui Xue, Yunqian Pan, Jun Zhang, Claes Wahlestedt, Francis J. Giles, Yu Chen, Martin E. Gleave, Collin C. Collins, Dingwei Ye, Yuzhuo Wang, Haojie Huang
EMBO MOLECULAR MEDICINE
(2019)
Article
Biochemistry & Molecular Biology
Simeng Wen, Yulei Wei, Chong Zen, Wei Xiong, Yuanjie Niu, Yu Zhao
Article
Oncology
Lei Chen, Hailong Liu, Yiyi Ji, Zehua Ma, Kai Shen, Xun Shangguan, Hongyang Qian, Yu Zhao, Chun-Wu Pan, Wei Xue
Summary: The study reveals that SHMT2 plays a role as a tumor proliferation suppressor and negatively regulates aggressive behavior in prostate cancer. Downregulation of SHMT2 is observed in advanced prostate cancer, and its depletion promotes proliferation and migration in prostate cancer cell lines. These findings highlight the importance of SHMT2 in prostate cancer and its potential for the development of new therapeutic strategies.
EXPERIMENTAL CELL RESEARCH
(2022)
Article
Multidisciplinary Sciences
Nan Niu, Fang Qiu, Qianshi Xu, Guijin He, Xi Gu, Wenbin Guo, Dianlong Zhang, Zhigao Li, Yi Zhao, Yong Li, Ke Li, Hao Zhang, Peili Zhang, Yuanxi Huang, Gangling Zhang, Hongbin Han, Zhengang Cai, Pengfei Li, Hong Xu, Guanglei Chen, Jinqi Xue, Xiaofan Jiang, Alireza Hamidian Jahromi, Jinshi Li, Yu Zhao, Eduardo de Faria Castro Fleury, Shiwen Huo, Huajun Li, Guy Jerusalem, Domenico Tripodi, Tong Liu, Xinyu Zheng, Caigang Liu
Summary: This study reports the results of an oral neoadjuvant therapy in treatment-naive patients with triple-positive breast cancer, showing positive clinical efficacy and safety with no serious adverse events or treatment-related deaths.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, Research & Experimental
Yu Zhao, Simeng Wen, Hang Li, Chun-Wu Pan, Yulei Wei, Ting Huang, Zhaochen Li, Yinhui Yang, Saijun Fan, Yingyi Zhang
Summary: This study identified bone-specific m6A-modified eRNA as a novel predictor for radiotherapy resistance in bone metastatic prostate cancer (mPCa). The RNA-binding protein KHSRP was found to play a functional role in inhibiting RNA degradation, thus contributing to radiotherapy resistance. Inhibition of the MLXIPe/KHSRP/PSMD9 regulatory complex was shown to suppress tumor growth and sensitize mPCa to radiotherapy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Dong Dai, Jiang Yu, Ting Huang, Yansheng Li, Ziyang Wang, Shuangmeng Yang, Shuai Li, Yanli Li, Wenfeng Gou, Deguan Li, Wenbin Hou, Saijun Fan, Yiliang Li, Yu Zhao
Summary: In this study, a novel tissue-specific gene CDK19 was found to be overexpressed in high-risk metastatic prostate cancer, and its expression correlated with metastatic status and tumor staging. Ga-68-CDK19 PET/CT was shown to be effective in detecting lesions with or without PSMA in vitro, in vivo, and in the PDX model. These findings suggest that Ga-68-CDK19 may be a predictive biomarker for PET scans in prospective cohorts and may help identify molecular types of prostate cancer independent of PSMA.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Chemistry, Multidisciplinary
Hang Li, Shuya Zhao, Mian Jiang, Tong Zhu, Jinjian Liu, Guoxing Feng, Lu Lu, Jiali Dong, Xin Wu, Xin Chen, Yu Zhao, Saijun Fan
Summary: This study found that exosomes derived from mice exposed to total body irradiation can protect recipient mice against radiation-induced gut injury. MiR-142, highly expressed in exosomes, plays a key role in mediating the protective effect against radiation enteritis by improving the intestinal microenvironment. Biomodification of exosomes through enhancing miR-142 expression and intestinal specificity can further improve the protection against radiation enteritis.
Article
Cell Biology
Wenxuan Li, Xinyue Wang, Yinping Dong, Qidong Huo, Tongpeng Yue, Xin Wu, Lu Lu, Junling Zhang, Yu Zhao, Hui Dong, Deguan Li
Summary: Radiotherapy induces premature aging effects in survivors, but effective methods for preventing this are lacking. This study evaluated the therapeutic effects of nicotinamide riboside on premature aging mice. The results showed that nicotinamide riboside treatment reversed aging phenotypes, improved serum metabolism, and restored the regenerative capacity of hematopoietic stem cells. These findings suggest that nicotinamide riboside has potential as a therapeutic agent for radiation-exposed populations and patients receiving radiotherapy.
Article
Medicine, Research & Experimental
Yinghui Li, Chaoqun Wang, Huier Gao, Jiali Gu, Yiran Zhang, Yingyi Zhang, Min Xie, Xuelian Cheng, Ming Yang, Wenshan Zhang, Yafang Li, Mei He, Hui Xu, Hexiao Zhang, Qing Ji, Tianhua Ma, Sheng Ding, Yu Zhao, Yingdai Gao
Summary: This study identified a specific KDM4 inhibitor, SD49-7, for resistant leukemia therapy, demonstrating its ability to inhibit the progression of leukemia stem cells (LSCs) and overcome resistance to traditional treatments.
Meeting Abstract
Oncology
Rachael Vaubel, Ann Mladek, Yu Zhao, Shiv K. Gupta, Minjee Kim, Afroz S. Mohammad, Katrina Bakken, Lihong He, Zeng Hu, Danielle M. Burgenske, Brett L. Carlson, William F. Elmquist, Jann Sarkaria
Meeting Abstract
Oncology
Jianxiong Ji, Emily Smith, Paige Sarkaria, Ann Mladek, Surabhi Talele, Katelyn Swanson, Afroz S. Mohammad, Wenjuan Zhang, Lihong He, Zeng Hu, Yu Zhao, Jiajia Chen, Margaret A. Connors, Kendra A. Porath, Katrina K. Bakken, Sonja Dragojevic, Brett L. Carlson, Shiv K. Gupta, Danielle M. Burgenske, Gaspar J. Kitange, William F. Elmquist, Jann Sarkaria
Article
Oncology
Yinhui Yang, Yang Bai, Yundong He, Yu Zhao, Jiaxiang Chen, Linlin Ma, Yunqian Pan, Michael Hinten, Jun Zhang, R. Jeffrey Karnes, Manish Kohli, Jennifer J. Westendorf, Benyi Li, Runzhi Zhu, Haojie Huang, Wanhai Xu
CLINICAL CANCER RESEARCH
(2018)